Centessa Pharmaceuticals Limited (CNTA): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
CNTA Stock Price Chart Interactive Chart >
CNTA Price/Volume Stats
|Current price||$16.80||52-week high||$26.90|
|Prev. close||$16.18||52-week low||$13.34|
|Day high||$17.14||Avg. volume||202,812|
|50-day MA||$19.29||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||1.51B|
Centessa Pharmaceuticals Limited (CNTA) Company Bio
Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.
Most Popular Stories View All
CNTA Latest News Stream
|Loading, please wait...|
CNTA Latest Social Stream
View Full CNTA Social Stream
Latest CNTA News From Around the Web
Below are the latest news stories about Centessa Pharmaceuticals plc that investors may wish to consider to help them evaluate CNTA as an investment opportunity.
Centessa Pharmaceuticals Appoints David Grainger, PhD, a Leading Biotech Entrepreneur, as Chief Innovation Officer
Industry veteran with decades of experience in company formation, scientific research, and drug development to join executive leadership team to accelerate pipeline potentialBOSTON and LONDON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today announced that David Grainger, PhD, has been appointe
~ New $300 million facility, combined with Company’s cash balance as of June 30, 2021, provides access to over $900 million to advance development programs and enable pursuit of strategic business development opportunities ~BOSTON and LONDON, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Centessa” or “Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patie
Centessa Pharmaceuticals PLC ADR (NASDAQ: CNTA), in partnership with its subsidiary ApcinteX Limited announced that results from its ongoing first-in-human proof-of-concept study to analyze SerpinPC in severe hemophilia A and B patients are positive. This news automatically pushed the Pharma stock up by 20% on Thursday morning. The study demonstrates that SerpinPC is well-tolerated  The post Heres why Centessa Pharma is up 20% on Thursday morning appeared first on Invezz .
Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis
~ 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~ ~ SerpinPC observed to be well-tolerated ~ ~ Company has initiated planning for global registrational program ~ ~ Conference call and webcast scheduled for today at 8:30 a.m. EDT ~ CAMBRIDGE, Mass. and LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc ("Company") (NASDAQ: CNTA ), together with subsidiary ApcinteX Limited ("ApcinteX"), today announced positive topline results from the Phase 2a part of AP-0101, the six-month repeat dose portion of its ongoing first-in-human proof-of-concept study evaluating SerpinPC in severe hemophilia A and B patients. AP-0101 is a Phase 1/2a proof-of-concept study evaluating ...
Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis
~ 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~ ~ SerpinPC observed to be well-tolerate
CNTA Price Returns